Navigation Links
InDex Pharmaceuticals Will Participate in the European Crohn's and Colitis Organisation (ECCO) Congress
Date:1/23/2017

STOCKHOLM, Sweden, Jan 23, 2017 /PRNewswire/ --

InDex Pharmaceuticals Holding AB (publ) today announced that the company will have two posters at the 12th congress of the European Crohn's and Colitis Organisation (ECCO). The ECCO congress is the largest congress in the world with a specific focus on inflammatory bowel disease (IBD). The congress is held in Barcelona, Spain on February 15-18, 2017.

"We are pleased to again having been selected to present data at the largest IBD congress in the world and that our results continue to meet considerable interest from the medical expertise", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "Furthermore, this year's congress coincides with the preparations for our next clinical study with the drug candidate cobitolimod for the treatment of ulcerative colitis. Participating in the congress allows us to have an active dialogue with the leading experts in the field and to promote the CONDUCT-study."

Both posters will be presented during the poster session on Friday February 17. The first poster has the title Binding properties of human TLR-9 receptor to cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development, and shows the binding affinity of cobitolimod to the receptor Toll-like receptor 9 (TLR9). The second poster has the title IL-10 induction properties of the TLR-9 agonist cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development and shows that cobitolimod can induce a dose dependent release in vitro of the anti-inflammatory cytokine IL-10 from immune cells obtained from both healthy individuals and ulcerative colitis patients. 

Abstracts of the posters will be available on the ECCO homepage (www.ecco-ibd.eu) at the end of January.

For more information, please contact:

Peter Zerhouni,
CEO
Phone: +46-8-508-847-35
E-mail: peter.zerhouni@indexpharma.com

About The European Crohn's and Colitis Organisation (ECCO)

ECCO is the largest forum for specialists in inflammatory bowel disease (IBD) in the world. ECCO produces scientific guidelines for the treatment of IBD, organises educational activities, promotes research and represents IBD specialists, and works with patient associations and industry to reduce the burden of disease for the patients. The annual congress attracted more than 5,000 delegates in 2016 and is the largest IBD congress in the world.

Cobitolimod in brief

Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct® and DIMS0150.

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-will-participate-in-the-european-crohn-s-and-colitis-organisation--ecco--congr,c2171330

The following files are available for download:

http://mb.cision.com/Main/9612/2171330/617525.pdf

PDF

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/index-pharmaceuticals-will-participate-in-the-european-crohns-and-colitis-organisation-ecco-congress-300394558.html


'/>"/>
SOURCE Index Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Cal INDEX and Inland Empire HIE will merge to form Californias largest health information exchange; former White House technology advisor named CEO
2. Aralez Added To The NASDAQ Biotechnology Index
3. Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index
4. CVS Health Achieves 100 Percent on 2017 Corporate Equality Index for Third Consecutive Year
5. Pulmatrix Added to Russell Microcap Index
6. Confidence Wanes as Uncertainty Builds in the Q4 2015 Biopharma CEO Confidence Index
7. Blueprint Medicines Added to NASDAQ Biotechnology Index
8. Egalet Added to NASDAQ Biotechnology Index
9. Teligent, Inc. Added To NASDAQ Biotechnology Index (NBI)
10. Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundations Corporate Equality Index
11. Boston Scientific Scores Perfect 100 on Human Rights Campaigns 2016 Corporate Equality Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... “Introducing our product on QVC is something we all worked hard to achieve for many ... than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. “We ...
(Date:6/20/2017)... ... ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the Journal ... Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among his other ... Co-Chair of The Fenway Institute, a member of the US President’s Emergency Plan for ...
(Date:6/20/2017)... ... June 20, 2017 , ... MindTouch , the leading ... proud to announce Touchpoints integrations. MindTouch Touchpoints easily integrate product documentation ... to provide a seamless customer experience. , Truly “plug and play,” Touchpoints are ...
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the ... are currently accepting new patients at their practice for these custom clear aligners. These ... is why they offer the latest in modern dental techniques to ensure that all ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished Sun Corridor ... Program selected Wisdom Natural Brands (WNB), and 16 other businesses from Pima, Pinal, ...
Breaking Medicine News(10 mins):